Tranexamic acid in variceal bleeding revisited

Affiliations

Comment

Krithivasan P Raman et al. Hepatology. 2024.

. 2024 Aug 1;80(2):257-259.

doi: 10.1097/HEP.0000000000000861. Epub 2024 Mar 19.

No abstract available

Comment on

Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: A randomized controlled trial.
Kumar M, Venishetty S, Jindal A, Bihari C, Maiwall R, Vijayaraghavan R, Saggere Muralikrishna S, Arora V, Kumar G, Sarin SK. Kumar M, et al. Hepatology. 2024 Aug 1;80(2):376-388. doi: 10.1097/HEP.0000000000000817. Epub 2024 Mar 5. Hepatology. 2024. PMID: 38441903 Clinical Trial.

1. Port RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study. Lancet. 2000;355:1303–1309.
1. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: A randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17:1–79.
1. Fletcher AP, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: Its cause and consequences. J Clin Invest. 1964;43:681–695.
1. Gluud LL, Klingenberg SL, Langholz SE. Systematic review: tranexamic acid for upper gastrointestinal bleeding. Aliment Pharmacol amp Ther. 2008;27:752–758.
1. Roberts I, Shakur-Still H, Afolabi A, Akere A, Arribas M, Brenner A, et al. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): An international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:1927–1936.